David Anthony Provenzano
Research Subjects
David Anthony Provenzano has a total of 304 co-authors. Here are the top co-authors by number of shared publications:
- Christine Hunt
Anesthesiology - Pain Medicine, Mayo Clinic, Rochester, Minnesota, USA
12 shared publications - Jason S. Kilgore
Washington & Jefferson College, Washington, PA, USA
7 shared publications - Samer Narouze
University Hospitals of Cleveland, Cleveland, Ohio, USA
7 shared publications - Ameet S. Nagpal
Medical University of South Carolina College of Medicine, Charleston, SC, USA
6 shared publications - Honorio T. Benzon
Department of Anesthesiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
6 shared publications - Steven Paul Cohen
Northwestern University Feinberg School of Medicine
6 shared publications
Latest Publications
- Open Access
- 21 October 2026
- Published by Elsevier in Interventional Pain Medicine
- Vol. 5 (4)
National and state-level analysis of peripheral nerve stimulation reimbursement patterns
- 21 October 2026
- Published by Elsevier in Interventional Pain Medicine
- Vol. 5 (4)
Open AccessNational and state-level analysis of peripheral nerve stimulation reimbursement patterns
- 10 August 2026
- Published by BMJ in Regional Anesthesia & Pain Medicine
Limited predictive utility of spinal cord stimulation trial pain metrics for post-implant outcomes
Background: This study evaluated the predictive value of pain outcomes reported during spinal cord stimulation (SCS) trialing for short-term, intermediate-term, and long-term post-implantation pain relief, and whether baseline patient characteristics modify these relationships. Methods: A retrospective review identified 124 patients who underwent SCS trial and implantation between 2015 and 2022 with a minimum of 6-months follow-up. Pain outcomes included numeric rating scale pain score (NRS), patient-reported percent pain relief (PR-PPR), and calculated percent pain relief (C-PPR) post-trial and at short-term (ST) 1–6 months (>1 to ≤6 months), intermediate term (IT) 6–15 months (>6 to ≤15 months), long-term (LT) 15–24 months (>15 to ≤24 months), and extended long-term (ELT) 24–36 months (>24 to ≤36 months) post-implantation. Univariable linear and logistic regression assessed predictive value, while Bland-Altman analysis and Lin’s concordance correlation coefficient (CCC) evaluated agreement between PR-PPR and C-PPR. Interaction modeling assessed effect modification of baseline covariates. Results: Patients experienced significant pain reduction following trial (∆NRS 4.7; 95% CI 4.3 to 5.2), with sustained, but attenuating, benefit through 36 months. ∆NRS demonstrated the strongest predictive value (peak R²=0.32 at 15–24 months), though overall explanatory power was modest. In adjusted models, post-trial NRS was the strongest predictor of achieving ≥50% long-term pain relief (OR 0.70, p=0.002). Bland-Altman analysis showed a mean difference of 10 percentage points between PR-PPR and C-PPR (95% limits of agreement −36% to +56%) with poor overall agreement (CCC=0.36). Greater than 50% PR-PPR was maintained in 81.5% at 1–6 months and 70.2% at 24–36 months, with no significant differences between high and moderate trial responders. Covariate interaction modeling did not identify any consistent patient-specific modifiers. Conclusions: Trial-phase pain metrics demonstrated limited utility in explaining short, intermediate, and long-term pain relief. NRS-based measures showed the most consistent predictive value, while disagreement between PR-PPR and C-PPR raises concerns regarding the reproducibility of percentage-based metrics. These findings emphasize the need for refinement of reliable SCS trial predictors for post-implant pain relief outcomes.
- 10 August 2026
- Published by BMJ in Regional Anesthesia & Pain Medicine
Limited predictive utility of spinal cord stimulation trial pain metrics for post-implant outcomes
Background: This study evaluated the predictive value of pain outcomes reported during spinal cord stimulation (SCS) trialing for short-term, intermediate-term, and long-term post-implantation pain relief, and whether baseline patient characteristics modify these relationships. Methods: A retrospective review identified 124 patients who underwent SCS trial and implantation between 2015 and 2022 with a minimum of 6-months follow-up. Pain outcomes included numeric rating scale pain score (NRS), patient-reported percent pain relief (PR-PPR), and calculated percent pain relief (C-PPR) post-trial and at short-term (ST) 1–6 months (>1 to ≤6 months), intermediate term (IT) 6–15 months (>6 to ≤15 months), long-term (LT) 15–24 months (>15 to ≤24 months), and extended long-term (ELT) 24–36 months (>24 to ≤36 months) post-implantation. Univariable linear and logistic regression assessed predictive value, while Bland-Altman analysis and Lin’s concordance correlation coefficient (CCC) evaluated agreement between PR-PPR and C-PPR. Interaction modeling assessed effect modification of baseline covariates. Results: Patients experienced significant pain reduction following trial (∆NRS 4.7; 95% CI 4.3 to 5.2), with sustained, but attenuating, benefit through 36 months. ∆NRS demonstrated the strongest predictive value (peak R²=0.32 at 15–24 months), though overall explanatory power was modest. In adjusted models, post-trial NRS was the strongest predictor of achieving ≥50% long-term pain relief (OR 0.70, p=0.002). Bland-Altman analysis showed a mean difference of 10 percentage points between PR-PPR and C-PPR (95% limits of agreement −36% to +56%) with poor overall agreement (CCC=0.36). Greater than 50% PR-PPR was maintained in 81.5% at 1–6 months and 70.2% at 24–36 months, with no significant differences between high and moderate trial responders. Covariate interaction modeling did not identify any consistent patient-specific modifiers. Conclusions: Trial-phase pain metrics demonstrated limited utility in explaining short, intermediate, and long-term pain relief. NRS-based measures showed the most consistent predictive value, while disagreement between PR-PPR and C-PPR raises concerns regarding the reproducibility of percentage-based metrics. These findings emphasize the need for refinement of reliable SCS trial predictors for post-implant pain relief outcomes.
- Open Access
- 28 July 2026
- Published by Elsevier in Interventional Pain Medicine
- Vol. 5 (3)
Incidence and etiology of impediments to spinal cord stimulator trial progression
- 28 July 2026
- Published by Elsevier in Interventional Pain Medicine
- Vol. 5 (3)
Open AccessIncidence and etiology of impediments to spinal cord stimulator trial progression
- Open Access
- 13 March 2026
- Published by BMJ in Regional Anesthesia & Pain Medicine
Prospective, non-inferiority, multicenter, randomized, single-blind clinical trial comparing cooled radiofrequency ablation to standard radiofrequency ablation to manage chronic facetogenic lumbar back pain
Background Low back pain is a leading cause of disability. Up to 45% of lumbar spine pain may be facetogenic. Both standard radiofrequency ablation (SRFA) and cooled radiofrequency ablation (CRFA) have been deployed to treat facetogenic pain. Methods Patients with lumbar facetogenic back pain, identified by two positive medial branch blocks (MBBs), were randomized to treatment with CRFA or SRFA. The primary endpoint was the proportion of subjects whose back pain decreased by ≥50% on the Numeric Rating Scale (NRS (usual): patient’s level of pain over the past 7 days) at 6 months, with subjects followed through 12 months. Secondary endpoints included changes in SF-36 (36-Item Short Form Health Survey) Physical Functioning (PF), Oswestry Disability Index (ODI), Global Perceived Effect scale (GPE), and EQ-5D-5L index (EuroQol's Health-Related Quality of Life Score using 5 levels over 5 dimensions). Enrollment (target 188) ended early after 18 months due to funding reallocation and strict Medicare criterion requiring ≥80% pain relief from dual MBBs. Results 74 patients (37 CRFA, 37 SRFA) were randomized, treated, and included in the intention-to-treat analysis. 61 patients (27 CRFA, 34 SRFA) completed the 6-month primary endpoint visit. Both CRFA and SRFA provided robust, statistically significant and clinically relevant reductions in NRS pain scores from baseline at every time point (p≤0.0001). CRFA met the predefined non-inferiority criterion relative to SRFA (p=0.0069), with a high proportion of both groups achieving ≥50% pain relief at the primary endpoint—74.1% with CRFA and 64.7% with SRFA. Although CRFA showed numerically greater reductions in NRS pain scores from baseline (–4.3 vs –3.4), both treatments exceeded the minimal clinically important difference threshold. No statistically significant differences in NRS scores were observed between groups at any time point, likely due to the premature termination of the study (only 52% enrolled). Both groups also showed significant and comparable improvements in NRS, EQ-5D-5L, ODI, SF-36 (PF), and GPE at 6 and 12 months. Conclusion Despite the smaller than intended sample size, due to early termination by the sponsor, this study demonstrated that with appropriate patient selection and proper procedural technique, both CRFA and SRFA can relieve chronic facetogenic low back pain, improve disability, function, and quality of life for 6–12 months. Trial registration number NCT04803149.
- 13 March 2026
- Published by BMJ in Regional Anesthesia & Pain Medicine
Open AccessProspective, non-inferiority, multicenter, randomized, single-blind clinical trial comparing cooled radiofrequency ablation to standard radiofrequency ablation to manage chronic facetogenic lumbar back pain
Background Low back pain is a leading cause of disability. Up to 45% of lumbar spine pain may be facetogenic. Both standard radiofrequency ablation (SRFA) and cooled radiofrequency ablation (CRFA) have been deployed to treat facetogenic pain. Methods Patients with lumbar facetogenic back pain, identified by two positive medial branch blocks (MBBs), were randomized to treatment with CRFA or SRFA. The primary endpoint was the proportion of subjects whose back pain decreased by ≥50% on the Numeric Rating Scale (NRS (usual): patient’s level of pain over the past 7 days) at 6 months, with subjects followed through 12 months. Secondary endpoints included changes in SF-36 (36-Item Short Form Health Survey) Physical Functioning (PF), Oswestry Disability Index (ODI), Global Perceived Effect scale (GPE), and EQ-5D-5L index (EuroQol's Health-Related Quality of Life Score using 5 levels over 5 dimensions). Enrollment (target 188) ended early after 18 months due to funding reallocation and strict Medicare criterion requiring ≥80% pain relief from dual MBBs. Results 74 patients (37 CRFA, 37 SRFA) were randomized, treated, and included in the intention-to-treat analysis. 61 patients (27 CRFA, 34 SRFA) completed the 6-month primary endpoint visit. Both CRFA and SRFA provided robust, statistically significant and clinically relevant reductions in NRS pain scores from baseline at every time point (p≤0.0001). CRFA met the predefined non-inferiority criterion relative to SRFA (p=0.0069), with a high proportion of both groups achieving ≥50% pain relief at the primary endpoint—74.1% with CRFA and 64.7% with SRFA. Although CRFA showed numerically greater reductions in NRS pain scores from baseline (–4.3 vs –3.4), both treatments exceeded the minimal clinically important difference threshold. No statistically significant differences in NRS scores were observed between groups at any time point, likely due to the premature termination of the study (only 52% enrolled). Both groups also showed significant and comparable improvements in NRS, EQ-5D-5L, ODI, SF-36 (PF), and GPE at 6 and 12 months. Conclusion Despite the smaller than intended sample size, due to early termination by the sponsor, this study demonstrated that with appropriate patient selection and proper procedural technique, both CRFA and SRFA can relieve chronic facetogenic low back pain, improve disability, function, and quality of life for 6–12 months. Trial registration number NCT04803149.
- Open Access
- 27 February 2026
- Published by BMJ in Regional Anesthesia & Pain Medicine
Multisociety multispecialty position statement on corticosteroid injections and influenza and COVID-19 vaccine administration
Background Corticosteroid injections (CSIs) are widely employed for chronic pain. These injections include peripheral nerve blocks and trigger point injections, injections of large appendicular joints, the axial facet and sacroiliac joints, and the epidural space. These injections may be performed in patients who have been recently vaccinated or plan to be vaccinated. This multisociety multispecialty position statement aims to develop evidence-based statements and recommendations (SRs) on the safe interval between CSIs and COVID-19 and influenza vaccine administration. Methods Development of the position statement was approved by the American Society of Regional Anesthesia and Pain Medicine Board of Directors and several other societies that agreed to participate. The scope of the SRs was agreed on to include the efficacy of COVID-19 and influenza vaccines, adverse events related to the CSIs, specifically the effect of CSIs on the hypothalamic–pituitary axis, incidence of COVID-19 in patients who had CSIs during the pandemic, incidence of influenza in patients who had CSIs during the influenza season, and recommend a reasonable interval between CSIs and COVID-19 and influenza vaccination 20 mg/day of prednisone s. Experts were assigned topics to perform a comprehensive literature review and draft SRs, which were refined and voted for consensus (≥75% agreement) using a modified Delphi process. A modified version of the US Preventive Services Task Force grading of evidence and strength of recommendation was followed. Results All SRs were approved by all participants after four rounds of discussion. The Practice Guidelines Committees and Boards of Directors of the participating societies also approved all SRs. If a vaccine has been recently administered or planned, then for non-urgent indications, the CSI should be offered at least 1 week before or after vaccine administration. For healthy patient(s), CSI, or vaccine administration may be performed without a 7-day interval after informed discussion with the patient and consent regarding the risk of blunted vaccine efficacy. For non-healthy patients, shared decision-making should include discussion of diminished vaccine effectiveness and the possibility of influenza or COVID-19 infection. Conclusions In this position statement, we provide recommendations on the optimal timing between CSIs and COVID-19 or influenza vaccine.
- 27 February 2026
- Published by BMJ in Regional Anesthesia & Pain Medicine
Open AccessMultisociety multispecialty position statement on corticosteroid injections and influenza and COVID-19 vaccine administration
Background Corticosteroid injections (CSIs) are widely employed for chronic pain. These injections include peripheral nerve blocks and trigger point injections, injections of large appendicular joints, the axial facet and sacroiliac joints, and the epidural space. These injections may be performed in patients who have been recently vaccinated or plan to be vaccinated. This multisociety multispecialty position statement aims to develop evidence-based statements and recommendations (SRs) on the safe interval between CSIs and COVID-19 and influenza vaccine administration. Methods Development of the position statement was approved by the American Society of Regional Anesthesia and Pain Medicine Board of Directors and several other societies that agreed to participate. The scope of the SRs was agreed on to include the efficacy of COVID-19 and influenza vaccines, adverse events related to the CSIs, specifically the effect of CSIs on the hypothalamic–pituitary axis, incidence of COVID-19 in patients who had CSIs during the pandemic, incidence of influenza in patients who had CSIs during the influenza season, and recommend a reasonable interval between CSIs and COVID-19 and influenza vaccination 20 mg/day of prednisone s. Experts were assigned topics to perform a comprehensive literature review and draft SRs, which were refined and voted for consensus (≥75% agreement) using a modified Delphi process. A modified version of the US Preventive Services Task Force grading of evidence and strength of recommendation was followed. Results All SRs were approved by all participants after four rounds of discussion. The Practice Guidelines Committees and Boards of Directors of the participating societies also approved all SRs. If a vaccine has been recently administered or planned, then for non-urgent indications, the CSI should be offered at least 1 week before or after vaccine administration. For healthy patient(s), CSI, or vaccine administration may be performed without a 7-day interval after informed discussion with the patient and consent regarding the risk of blunted vaccine efficacy. For non-healthy patients, shared decision-making should include discussion of diminished vaccine effectiveness and the possibility of influenza or COVID-19 infection. Conclusions In this position statement, we provide recommendations on the optimal timing between CSIs and COVID-19 or influenza vaccine.
- 22 February 2026
- Published by Oxford University Press (OUP) in Pain Medicine
- Vol. 27 (8) , 863-866
CMS proposed restrictions on peripheral nerve blocks and procedures for chronic pain: clinical, ethical, and policy implications for millions of Americans
- 22 February 2026
- Published by Oxford University Press (OUP) in Pain Medicine
- Vol. 27 (8) , 863-866
CMS proposed restrictions on peripheral nerve blocks and procedures for chronic pain: clinical, ethical, and policy implications for millions of Americans
- 22 January 2026
- Published by BMJ in Regional Anesthesia & Pain Medicine
Multisociety multispecialty consensus recommendations on corticosteroid injections for facet joint and sacroiliac joint pain
Background: Corticosteroid injections (CSIs) are widely employed in facet and sacroiliac joint pain. Similar to CSIs at other sites (peripheral nerve blocks, joints, epidural), these injections are associated with potential adverse events. These multisociety consensus recommendations aim to develop evidence-based statements and recommendations on the safe use of CSIs in facet joint and sacroiliac joint injections. Methods: Development of the consensus recommendations was approved by the American Society of Regional Anesthesia and Pain Medicine Board of Directors and several other societies that agreed to participate. The scope of statements and recommendations was agreed on to include safety of the injection technique (landmark-guided, ultrasound, or radiology-aided injections); effect of the addition of the corticosteroid on effectiveness (vs local anesthetic or saline); and adverse events related to the injection. Experts were assigned topics to perform a comprehensive literature review and draft statements and recommendations, which were refined and voted for consensus (>75% agreement) using a modified Delphi process. A modified version of the US Preventive Services Task Force grading of evidence and strength of recommendation was followed. Results: All statements and recommendations were approved by all participants after four rounds of discussion. The Practice Guidelines Committees and Boards of Directors of the participating societies also approved all statements and recommendations. Injection of corticosteroid into the facet joint in patients with joint inflammation may relieve pain and improves function. Intra-articular, extra-articular (periarticular), and combined administration are effective for sacroiliac joint injections. No dose-response studies exist, but CSIs containing 10 mg of methylprednisolone or triamcinolone per facet joint and 40 mg per sacroiliac joint (SIJ) (or their respective pharmacologic equivalents) are reasonable. Conclusions: In this practice recommendation, we provide statements and recommendations on facet and sacroiliac joint CSIs, the optimal doses, and intervals and criteria for repeating the CSIs in patients with facet joint and sacroiliac joint pain.
- 22 January 2026
- Published by BMJ in Regional Anesthesia & Pain Medicine
Multisociety multispecialty consensus recommendations on corticosteroid injections for facet joint and sacroiliac joint pain
Background: Corticosteroid injections (CSIs) are widely employed in facet and sacroiliac joint pain. Similar to CSIs at other sites (peripheral nerve blocks, joints, epidural), these injections are associated with potential adverse events. These multisociety consensus recommendations aim to develop evidence-based statements and recommendations on the safe use of CSIs in facet joint and sacroiliac joint injections. Methods: Development of the consensus recommendations was approved by the American Society of Regional Anesthesia and Pain Medicine Board of Directors and several other societies that agreed to participate. The scope of statements and recommendations was agreed on to include safety of the injection technique (landmark-guided, ultrasound, or radiology-aided injections); effect of the addition of the corticosteroid on effectiveness (vs local anesthetic or saline); and adverse events related to the injection. Experts were assigned topics to perform a comprehensive literature review and draft statements and recommendations, which were refined and voted for consensus (>75% agreement) using a modified Delphi process. A modified version of the US Preventive Services Task Force grading of evidence and strength of recommendation was followed. Results: All statements and recommendations were approved by all participants after four rounds of discussion. The Practice Guidelines Committees and Boards of Directors of the participating societies also approved all statements and recommendations. Injection of corticosteroid into the facet joint in patients with joint inflammation may relieve pain and improves function. Intra-articular, extra-articular (periarticular), and combined administration are effective for sacroiliac joint injections. No dose-response studies exist, but CSIs containing 10 mg of methylprednisolone or triamcinolone per facet joint and 40 mg per sacroiliac joint (SIJ) (or their respective pharmacologic equivalents) are reasonable. Conclusions: In this practice recommendation, we provide statements and recommendations on facet and sacroiliac joint CSIs, the optimal doses, and intervals and criteria for repeating the CSIs in patients with facet joint and sacroiliac joint pain.
- Open Access
- 30 November 2025
- Published by Oxford University Press (OUP) in Pain Medicine
- Vol. 26 (12) , 817-917
Consensus practice guidelines on sacroiliac joint complex pain from a multispecialty, international working group
Background: The past two decades have witnessed tremendous growth in the appreciation and treatment of sacroiliac joint (SIJ) complex pain, including anatomical dissections that shed light on innervation, an appreciation for the contribution of extra-articular components to SIJ complex pain, the advent of radiofrequency ablation (RFA) and a host of minimally invasive surgical techniques. Yet, there is no standardization on diagnosis and treatment paradigms. Methods: In February 2023, the Boards of Directors for the American Academy of Pain Medicine (AAPM) and American Society of Regional Anesthesia & Pain Medicine (ASRA-PM) approved the development of multispecialty guidelines on SIJ complex pain. Thirty partner organizations with clinical and scientific interests in SIJ complex pain were identified, and formal letters of request-for-participation were sent to each, along with a request for nominees to serve on the committee. Twenty five organizations agreed to participate in addition to the Departments of Defense and Veterans Affairs. A steering committee developed 21 questions, which spanned criteria for diagnosis, non-interventional and interventional treatments including surgery, technical parameters on how to optimize results, and what constitutes positive outcomes. Questions were methodically assigned to specialized modules comprising 4-5 members with complementary expertise, who collaborated with the Subcommittee Lead and one of three Committee Chairs to develop preliminary drafts. Following thorough revisions, these drafts were subsequently submitted to the full committee for comprehensive review. A modified Delphi method was used in which the answers to questions were sent to the committee en bloc and comments were returned in a non-blinded fashion to the Chairs, who incorporated the comments and sent out revised versions until consensus was achieved. During a committee meeting before commencement, it was agreed that recommendations would be noted when there was >50% agreement among committee members, but that a formal recommendation would require ≥75% consensus. Results: Twenty-one organizations formally endorsed the guidelines. The American Society of Anesthesiologists, and American Academy of Physical Medicine & Rehabilitation, and the North American Spine Society affirmed the benefit of the guidelines but did not officially endorse them. The American Academy of Neurology declined to affirm the benefit of the guidelines citing “lack of relevance to their membership.” Per policies, while the Departments of Defense and Veterans Affairs did not formally review the guidelines for endorsement, their representatives approved them. In addition to being endorsed or the benefit affirmed by all voting organizations, complete consensus from committee members was obtained on all 21 questions. On 2 recommendations, there were dissensions from 3 societies who thought that selecting patients for sacral lateral branch RFA and minimally invasive fusion should be based on ≥75% relief from 2 blocks instead of at least 50% relief from a single block before RFA, and greater than 50% pain relief with documented functional improvement after a single block before fusion. One additional society (Latin American Society of Regional Anesthesia) abstained on the statement that the evidence is stronger for extra-articular than intra-articular injections. The committee found that a battery of physical exam tests has reasonable sensitivity, but lower specificity, for identifying intra-articular but not extra-articular pathology, with negative tests having greater predictive value than positive ones. Intra-articular injections have diagnostic validity for SIJ intra-articular, but not extra-articular pain. There is unclear or negative evidence for imaging. The prevalence rates of intra-articular and extra-articular pathology are comparable, with both intra- and extra-articular steroid injections providing at least 4 weeks of relief in well-selected patients. However, the evidence is slightly stronger for extra-articular corticosteroid injections to provide short-term relief. The evidence base for non-interventional therapies is indirect, extrapolated mostly from low back pain studies. There is weak evidence supporting dextrose-based prolotherapy and platelet-rich plasma to provide at least 3 months of pain relief. There is strong evidence for sacral lateral branch RFA to provide relief for at least 6 months in individuals with extra-articular pathology, with face validity and indirect evidence from randomized trials supporting sacral lateral branch blocks as a prognostic tool. There is stronger evidence for larger lesions or more aggressive lesioning strategies than for less stringent techniques. There is weak evidence to support non-steroidal anti-inflammatory drugs to prevent neuritis after RFA, and in most cases anticoagulation does not require cessation in the periprocedural perioid. With an aggressive lesioning strategy, sensory stimulation provides minimal therapeutic benefit, with weak, extrapolated evidence that motor stimulation can provide safety benefit. The cutoff to designate diagnostic or prognostic blocks as positive is most commonly set at 50%, with higher values not shown to improve outcomes for more definitive procedures; for therapeutic treatment outcomes, the evidence supports a lower threshold of ≥30% pain relief or meaningful benefit on non-pain outcomes (eg, opioid cessation) for designation of a positive response. For carefully selected patients with intra-articular SIJ complex pain based on controlled blocks who have failed conservative therapies, there is weak or very weak evidence that minimally invasive SIJ fusion can provide benefit for at least one year. Conclusions: SIJ complex pain remains an underappreciated source of chronic low back pain, affecting between 15% and 30% of patients with axial pain predominantly below L5. Answers to many...
- 30 November 2025
- Published by Oxford University Press (OUP) in Pain Medicine
- Vol. 26 (12) , 817-917
Open AccessConsensus practice guidelines on sacroiliac joint complex pain from a multispecialty, international working group
Background: The past two decades have witnessed tremendous growth in the appreciation and treatment of sacroiliac joint (SIJ) complex pain, including anatomical dissections that shed light on innervation, an appreciation for the contribution of extra-articular components to SIJ complex pain, the advent of radiofrequency ablation (RFA) and a host of minimally invasive surgical techniques. Yet, there is no standardization on diagnosis and treatment paradigms. Methods: In February 2023, the Boards of Directors for the American Academy of Pain Medicine (AAPM) and American Society of Regional Anesthesia & Pain Medicine (ASRA-PM) approved the development of multispecialty guidelines on SIJ complex pain. Thirty partner organizations with clinical and scientific interests in SIJ complex pain were identified, and formal letters of request-for-participation were sent to each, along with a request for nominees to serve on the committee. Twenty five organizations agreed to participate in addition to the Departments of Defense and Veterans Affairs. A steering committee developed 21 questions, which spanned criteria for diagnosis, non-interventional and interventional treatments including surgery, technical parameters on how to optimize results, and what constitutes positive outcomes. Questions were methodically assigned to specialized modules comprising 4-5 members with complementary expertise, who collaborated with the Subcommittee Lead and one of three Committee Chairs to develop preliminary drafts. Following thorough revisions, these drafts were subsequently submitted to the full committee for comprehensive review. A modified Delphi method was used in which the answers to questions were sent to the committee en bloc and comments were returned in a non-blinded fashion to the Chairs, who incorporated the comments and sent out revised versions until consensus was achieved. During a committee meeting before commencement, it was agreed that recommendations would be noted when there was >50% agreement among committee members, but that a formal recommendation would require ≥75% consensus. Results: Twenty-one organizations formally endorsed the guidelines. The American Society of Anesthesiologists, and American Academy of Physical Medicine & Rehabilitation, and the North American Spine Society affirmed the benefit of the guidelines but did not officially endorse them. The American Academy of Neurology declined to affirm the benefit of the guidelines citing “lack of relevance to their membership.” Per policies, while the Departments of Defense and Veterans Affairs did not formally review the guidelines for endorsement, their representatives approved them. In addition to being endorsed or the benefit affirmed by all voting organizations, complete consensus from committee members was obtained on all 21 questions. On 2 recommendations, there were dissensions from 3 societies who thought that selecting patients for sacral lateral branch RFA and minimally invasive fusion should be based on ≥75% relief from 2 blocks instead of at least 50% relief from a single block before RFA, and greater than 50% pain relief with documented functional improvement after a single block before fusion. One additional society (Latin American Society of Regional Anesthesia) abstained on the statement that the evidence is stronger for extra-articular than intra-articular injections. The committee found that a battery of physical exam tests has reasonable sensitivity, but lower specificity, for identifying intra-articular but not extra-articular pathology, with negative tests having greater predictive value than positive ones. Intra-articular injections have diagnostic validity for SIJ intra-articular, but not extra-articular pain. There is unclear or negative evidence for imaging. The prevalence rates of intra-articular and extra-articular pathology are comparable, with both intra- and extra-articular steroid injections providing at least 4 weeks of relief in well-selected patients. However, the evidence is slightly stronger for extra-articular corticosteroid injections to provide short-term relief. The evidence base for non-interventional therapies is indirect, extrapolated mostly from low back pain studies. There is weak evidence supporting dextrose-based prolotherapy and platelet-rich plasma to provide at least 3 months of pain relief. There is strong evidence for sacral lateral branch RFA to provide relief for at least 6 months in individuals with extra-articular pathology, with face validity and indirect evidence from randomized trials supporting sacral lateral branch blocks as a prognostic tool. There is stronger evidence for larger lesions or more aggressive lesioning strategies than for less stringent techniques. There is weak evidence to support non-steroidal anti-inflammatory drugs to prevent neuritis after RFA, and in most cases anticoagulation does not require cessation in the periprocedural perioid. With an aggressive lesioning strategy, sensory stimulation provides minimal therapeutic benefit, with weak, extrapolated evidence that motor stimulation can provide safety benefit. The cutoff to designate diagnostic or prognostic blocks as positive is most commonly set at 50%, with higher values not shown to improve outcomes for more definitive procedures; for therapeutic treatment outcomes, the evidence supports a lower threshold of ≥30% pain relief or meaningful benefit on non-pain outcomes (eg, opioid cessation) for designation of a positive response. For carefully selected patients with intra-articular SIJ complex pain based on controlled blocks who have failed conservative therapies, there is weak or very weak evidence that minimally invasive SIJ fusion can provide benefit for at least one year. Conclusions: SIJ complex pain remains an underappreciated source of chronic low back pain, affecting between 15% and 30% of patients with axial pain predominantly below L5. Answers to many...
- Open Access
- 23 August 2025
- Published by Elsevier in Interventional Pain Medicine
- Vol. 4 (3) , 100623
Assessment of real-world, prospective outcomes in patients treated with cervical radiofrequency ablation for chronic pain (RAPID)
- 23 August 2025
- Published by Elsevier in Interventional Pain Medicine
- Vol. 4 (3) , 100623
Open AccessAssessment of real-world, prospective outcomes in patients treated with cervical radiofrequency ablation for chronic pain (RAPID)
- 22 August 2025
- Published by Wiley in Pain Practice
- Vol. 25 (7) , e70069
Delphi Consensus Revealing the Thoughts of Pain Management and Referral Specialties on the Use of SCS for Chronic Back Pain Patients Not Suitable for Spine Surgery
Introduction: Chronic back pain is a significant global healthcare challenge, with a lifetime incidence affecting approximately 80% of people worldwide. Most patients respond positively to nonsurgical management, while a substantial proportion of the remainder obtain relief from surgical therapy. For the minority of patients with chronic back pain who do not respond to conventional medical management (CMM) and are not candidates for spine surgery, spinal cord stimulation (SCS) may be a viable treatment option. This Delphi consensus focused on identifying the thoughts and opinions of pain management and referral specialties on the use of SCS in patients with chronic back pain who are not suitable for spine surgery.Methods: A steering group of US healthcare professionals specialized in spine surgery and chronic back pain management generated 35 statements across six main domains. Using a four‐point Likert scale, the survey was created and shared with a wider panel of specialists. Results were analyzed to produce an aggregated agreement level for each statement. The consensus threshold was set at 75% agreement, which is defined as strong consensus, and ≥ 90% agreement was considered powerful consensus.Results: A total of 211 responses were received from the following specialties: pain physician (18%; n = 38), physical therapist (18%; n = 38), orthopedic surgeon (18%; n = 37), neurosurgeon (17%; n = 36), primary care physician (15%; n = 32), and musculoskeletal radiologist (14%; n = 30). Of the 35 consensus statements developed for broader testing, 30/35 (86%) achieved consensus; 18 (51%) of which achieved ≥ 90% agreement. The remaining five (15%) statements failed to achieve consensus among the wider panel.Conclusion: Based on the agreement scores, the steering group agreed on seven key findings to consider for pain management in patients with chronic back pain who are not candidates for spine surgery. These findings are opinion‐based and are meant to be a starting point to help identify appropriate patients who may benefit from SCS therapy and when an evaluation for SCS candidacy should be considered.
- 22 August 2025
- Published by Wiley in Pain Practice
- Vol. 25 (7) , e70069
Delphi Consensus Revealing the Thoughts of Pain Management and Referral Specialties on the Use of SCS for Chronic Back Pain Patients Not Suitable for Spine Surgery
Introduction: Chronic back pain is a significant global healthcare challenge, with a lifetime incidence affecting approximately 80% of people worldwide. Most patients respond positively to nonsurgical management, while a substantial proportion of the remainder obtain relief from surgical therapy. For the minority of patients with chronic back pain who do not respond to conventional medical management (CMM) and are not candidates for spine surgery, spinal cord stimulation (SCS) may be a viable treatment option. This Delphi consensus focused on identifying the thoughts and opinions of pain management and referral specialties on the use of SCS in patients with chronic back pain who are not suitable for spine surgery.Methods: A steering group of US healthcare professionals specialized in spine surgery and chronic back pain management generated 35 statements across six main domains. Using a four‐point Likert scale, the survey was created and shared with a wider panel of specialists. Results were analyzed to produce an aggregated agreement level for each statement. The consensus threshold was set at 75% agreement, which is defined as strong consensus, and ≥ 90% agreement was considered powerful consensus.Results: A total of 211 responses were received from the following specialties: pain physician (18%; n = 38), physical therapist (18%; n = 38), orthopedic surgeon (18%; n = 37), neurosurgeon (17%; n = 36), primary care physician (15%; n = 32), and musculoskeletal radiologist (14%; n = 30). Of the 35 consensus statements developed for broader testing, 30/35 (86%) achieved consensus; 18 (51%) of which achieved ≥ 90% agreement. The remaining five (15%) statements failed to achieve consensus among the wider panel.Conclusion: Based on the agreement scores, the steering group agreed on seven key findings to consider for pain management in patients with chronic back pain who are not candidates for spine surgery. These findings are opinion‐based and are meant to be a starting point to help identify appropriate patients who may benefit from SCS therapy and when an evaluation for SCS candidacy should be considered.